البورد العراقي للصيدلة السريرية - EXJADE® (deferasirox) is indicated in the management of chronic iron overload in patients with transfusion-dependent anemias aged 6 years or older Take Exjade on an empty stomach
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use EXJADE safely and effect
![Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study - ScienceDirect Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1079979615300103-gr1.jpg)
Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study - ScienceDirect
![Effects of deferasirox dose and decreasing serum ferritin concentrations on kidney function in paediatric patients: an analysis of clinical laboratory data from pooled clinical studies - The Lancet Child & Adolescent Health Effects of deferasirox dose and decreasing serum ferritin concentrations on kidney function in paediatric patients: an analysis of clinical laboratory data from pooled clinical studies - The Lancet Child & Adolescent Health](https://www.thelancet.com/cms/attachment/e8e148f1-f496-441b-92bf-d352afd2c290/gr1.gif)
Effects of deferasirox dose and decreasing serum ferritin concentrations on kidney function in paediatric patients: an analysis of clinical laboratory data from pooled clinical studies - The Lancet Child & Adolescent Health
![Pharmacological and clinical evaluation of deferasirox formulations for treatment tailoring | Scientific Reports Pharmacological and clinical evaluation of deferasirox formulations for treatment tailoring | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-021-91983-w/MediaObjects/41598_2021_91983_Fig1_HTML.png)